Patients from 22+ countriesPlan your visit →
lutetium-therapy
Blog

Latest from research and the clinic.

New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.

Medically reviewedUpdated 14 Nov 2024
Caregiver Treatment Decisions12 Aug 2026

Caregiver Burnout During Lu-177 PSMA Therapy

Caring for a loved one on Lu-177 PSMA therapy for mCRPC is more demanding than most people expect. This article helps spouses and adult children recognize caregiver burnout, follow radiation safety rules at home, and sustain their own health through treatment.

8 min read
Patient Journey11 Aug 2026

Lu-177 PSMA Resistance and Next Steps for mCRPC

If lutetium Lu-177 PSMA therapy has stopped controlling your metastatic castration-resistant prostate cancer, you still have options. This article explains why resistance happens, how your team identifies it, and what the next treatment paths may look like.

9 min read
Access & Cost10 Aug 2026

Financing Your Lu-177 PSMA Treatment in India

In the United States, a full course of Pluvicto can exceed USD 250,000 in drug costs alone. This guide covers the medical tourism loans, hospital payment plans, and employer schemes that patients with mCRPC use to finance Lu-177 PSMA therapy in India.

9 min read
Considering Lu-177 Therapy9 Aug 2026

Will PRRT Control Your Carcinoid Syndrome Symptoms?

Carcinoid syndrome - flushing, diarrhea, and abdominal cramps driven by hormone-producing GEP-NETs - can persist even on somatostatin analogues. Research shows that PRRT using lutetium Lu-177 dotatate may reduce these hormone-driven symptoms alongside slowing tumour growth.

9 min read
Considering Lu-177 Therapy8 Aug 2026

Lu-177 PSMA Eligibility With Declining Kidney Function

Declining kidney function is one of the most common concerns men raise before starting Lu-177 PSMA therapy. This article explains how kidney health is assessed, what GFR thresholds mean in practice, and what options remain when kidney numbers are borderline or low.

8 min read
Treatment Abroad7 Aug 2026

Planning Your India Trip for Lu-177 PSMA Therapy

If your PSMA-PET scan confirms eligibility and India is on your radar, this guide covers the practical side: visas, flights, accommodation, and what to budget beyond the treatment cost itself.

8 min read
Treatment Abroad6 Aug 2026

PRRT in India: Real Travel Costs for International Patients

Traveling to India for PRRT? This guide breaks down what international NET patients actually spend on treatment, flights, visas, accommodation, and insurance - so you can build a realistic budget before you book anything.

8 min read
Lu-177 vs Standard-of-Care5 Aug 2026

Lu-177 PSMA vs Taxane Chemotherapy After Hormone Failure

When hormone therapy stops working in metastatic prostate cancer, two main options emerge: Lu-177 PSMA radioligand therapy and taxane chemotherapy. Which path fits your case depends on one factor above all others - whether your tumors show PSMA expression on a PET scan.

8 min read
Considering Lu-177 Therapy4 Aug 2026

Grade 1 NET and PRRT: When Lu-177 DOTATATE Can Wait

If your GEP-NET is Grade 1 and your disease is stable, PRRT with lutetium Lu-177 dotatate may not be the right next step yet. Learn what the evidence says about timing PRRT for low-grade neuroendocrine tumors - and when a Grade 1 NET does cross the threshold for treatment.

8 min read
Considering Lu-177 Therapy3 Aug 2026

When PSMA Imaging Is Negative in mCRPC: Lu-177 Eligibility Explained

Your PSA is climbing, but your scans show nothing. Learn why PSMA-PET imaging is the gating test for Lu-177 PSMA therapy, what a negative scan actually means, and what options remain in mCRPC.

8 min read
Caregiver Treatment Decisions2 Aug 2026

Lu-177 PSMA Caregiver Guide for mCRPC Families

If your husband, father, or partner is starting lutetium Lu-177 PSMA therapy for metastatic castration-resistant prostate cancer, this guide explains the radiation safety rules you must follow at home, which side effects to watch for between cycles, and how to protect your own health across a treatment course that may run six months or longer.

8 min read
Patient Journey31 Jul 2026

Preparing for Your PSMA PET Scan for Lu-177 Eligibility

A PSMA PET scan is the test that determines whether Lu-177 PSMA therapy may be an option for your metastatic prostate cancer. This guide covers how to prepare, what happens during imaging, and what your results mean for eligibility.

8 min read

How we choose what to write about

We focus on three kinds of content:

  1. Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
  2. Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
  3. India updates - new centers, new approvals, new policies that affect Indian and India-bound patients

Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

Blog - Page 4 - Lutetium Therapy Research, News, and Patient FAQs | lutetium-therapy